412 results on '"Zavascki, Alexandre P."'
Search Results
2. A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol
3. Comparison of vancomycin assays in patients undergoing hemodialysis
4. Association between acute disease severity and one-year quality of life among post-hospitalisation COVID-19 patients: Coalition VII prospective cohort study
5. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients
6. Melatonin for prevention of acute kidney injury in patients treated with intravenous polymyxin B: a double-blind, placebo-controlled randomized clinical trial
7. Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity
8. Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniaefrom bloodstream infections in hospitalized patients in Brazil
9. Clinical usefulness of tomographic standards for COVID-19 pneumonia diagnosis: Experience from a Brazilian reference center
10. Clinical Use of Polymyxin B
11. Vancomycin and creatinine determination in dried blood spots: Analytical validation and clinical assessment
12. A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol
13. Increased frequency of blaNDM in a tertiary care hospital in southern Brazil
14. Which trial do we need? One or two antimicrobials with anti-pseudomonal activity for the empirical treatment of Ventilator-associated pneumonia due to Gram-negative bacteria
15. Emergence of polymyxin B resistance in a polymyxin B-susceptible KPC-producing Klebsiella pneumoniae causing bloodstream infection in a neutropenic patient during polymyxin B therapy
16. Detection of Enterobacterales resistant to polymyxins using Rapid Polymyxins NP test
17. Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis
18. Dissemination of blaOXA-370 is mediated by IncX plasmids and the Tn6435 transposon
19. Low Doses of Colistimethate: Don't Rush In!
20. Population Pharmacokinetic Modeling of Free Plasma and Free Brain Concentrations of Ceftaroline in Healthy and Methicillin-Resistant Staphylococcus aureus-Infected Wistar Rats
21. Evaluation of clinical and microbiological factors related to mortality in patients with Gram-negative bacterial infections treated with ceftazidime–avibactam: A prospective multicentric cohort study
22. Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriacea mediastinitis
23. The changing epidemiology of Acinetobacter spp. producing OXA carbapenemases causing bloodstream infections in Brazil: a BrasNet report
24. Melatonin for prevention of acute kidney injury in patients treated with intravenous polymyxin B: a double-blind, placebo-controlled randomized clinical trial
25. Double-, single- and none-carbapenem-containing regimens for the treatment of carbapenem-resistant Enterobacterales (CRE) bloodstream infections: a retrospective cohort
26. Evaluation of Clinical Course of Gamma (P.1) Variant of Concern versus Lineages in Hospitalized Patients with COVID-19 in a Reference Center in Brazil
27. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium
28. Heteroresistance to Carbapenems in New Delhi Metallo-β-Lactamase-1–Producing Isolates: A Challenge for Detection?
29. Reply to Pai
30. Large hospital-wide outbreak of Paenibacillusspp pseudobacteremia associated with contaminated nonsterile gloves
31. Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens
32. Characteristics of Enterobacteriaceae Isolates Coharboring Distinct Carbapenemase Genes
33. Outbreak of Carbapenem-Resistant Providencia stuartii in an Intensive Care Unit
34. Polymyxin B Consumption and Incidence of Gram-Negative Bacteria Intrinsically Resistant to Polymyxins
35. Streptococcus pneumoniae appendicitis in an adult patient☆
36. Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients
37. Brazilʼs Family Health Strategy
38. High Endemic Rates of OXA-23-Producing Carbapenem-Resistant Acinetobacter baumannii Isolates Caused by the Persistence of Major Clones in Hospitals in a Brazilian City 5 Years After an Outbreak
39. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study
40. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
41. Invasive liver abscess syndrome with central nervous system involvement caused by hypermucoviscous Klebsiella pneumoniae: positive string test
42. Risk factors for KPC-producing Klebsiella pneumoniae bacteremia
43. Performance of polymyxin B Etest in a setting of high prevalence of KPC-producing Klebsiella pneumoniae
44. Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study
45. Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside
46. Combination therapy for carbapenem-resistant Gram-negative bacteria
47. Molecular characterization of Klebsiella pneumoniae carbapenemase-producing isolates in southern Brazil
48. Pharmacokinetics of intravenous polymyxin B in critically ill patients
49. Getting Ready for the Covid-19 Pandemic: Experience of a Brazilian Hospital
50. Fungal Thyroiditis: An Overview
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.